Zevra Therapeutics, Inc. Sublease Income
Zevra Therapeutics, Inc. (ZVRA) reported Sublease Income of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-08-05
- Zevra Therapeutics, Inc. sublease income for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. sublease income for the quarter ending 2026-03-31 was $26.00K, a 33.33% decline year-over-year.
- Zevra Therapeutics, Inc. sublease income for the quarter ending 2025-12-31 was $39.00K.
- Zevra Therapeutics, Inc. sublease income for the quarter ending 2025-09-30 was $27.00K, a 46.00% decline year-over-year.
- Zevra Therapeutics, Inc. sublease income for fiscal 2025 was $144.00K, a 12.50% increase from fiscal 2024.
- Zevra Therapeutics, Inc. sublease income for fiscal 2024 was $128.00K, a 18.47% decline from fiscal 2023.
- Zevra Therapeutics, Inc. sublease income for fiscal 2023 was $157.00K, a 0.00% change from fiscal 2022.
- Zevra Therapeutics, Inc. sublease income for fiscal 2022 was $157.00K, a 72.53% increase from fiscal 2021.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $26.00K 10-Q · filed 2026-08-05 | $65.00K derived: sum of 3 quarters · filed 2026-08-05 | $92.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-06 | $65.00K derived: sum of 2 quarters · filed 2026-05-06 | $92.00K derived: sum of 3 quarters · filed 2026-05-06 | $131.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $66.00K derived: sum of 2 quarters · filed 2026-03-09 | $105.00K derived: sum of 3 quarters · filed 2026-08-05 | $144.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $27.00K 10-Q · filed 2025-11-05 | $66.00K derived: sum of 2 quarters · filed 2026-08-05 | $105.00K 10-Q · filed 2025-11-05 | $105.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $39.00K 10-Q · filed 2026-08-05 | $78.00K 10-Q · filed 2026-08-05 | $78.00K derived: sum of 3 quarters · filed 2026-08-05 | $128.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $39.00K 10-Q · filed 2026-05-06 | $39.00K derived: sum of 2 quarters · filed 2026-05-06 | $89.00K derived: sum of 3 quarters · filed 2026-05-06 | $128.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $50.00K derived: sum of 2 quarters · filed 2026-03-09 | $89.00K derived: sum of 3 quarters · filed 2026-03-09 | $128.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $50.00K 10-Q · filed 2025-11-05 | $89.00K derived: sum of 2 quarters · filed 2025-11-05 | $128.00K 10-Q · filed 2025-11-05 | $168.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $39.00K 10-Q · filed 2025-08-12 | $78.00K 10-Q · filed 2025-08-12 | $118.00K derived: sum of 3 quarters · filed 2025-08-12 | $157.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $39.00K 10-Q · filed 2025-05-13 | $79.00K derived: sum of 2 quarters · filed 2025-05-13 | $118.00K derived: sum of 3 quarters · filed 2025-05-13 | $157.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $79.00K derived: sum of 2 quarters · filed 2025-03-12 | $118.00K derived: sum of 3 quarters · filed 2025-03-12 | $157.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $39.00K 10-Q · filed 2024-11-13 | $78.00K derived: sum of 2 quarters · filed 2024-11-13 | $117.00K 10-Q · filed 2024-11-13 | $157.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $39.00K 10-Q · filed 2024-08-14 | $78.00K 10-Q · filed 2024-08-14 | $118.00K derived: sum of 3 quarters · filed 2024-08-14 | $157.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $39.00K 10-Q · filed 2024-05-09 | $79.00K derived: sum of 2 quarters · filed 2024-05-09 | $118.00K derived: sum of 3 quarters · filed 2024-05-09 | $157.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $79.00K derived: sum of 2 quarters · filed 2024-04-01 | $118.00K derived: sum of 3 quarters · filed 2024-04-01 | $157.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $39.00K 10-Q · filed 2023-11-07 | $78.00K derived: sum of 2 quarters · filed 2023-11-07 | $117.00K 10-Q · filed 2023-11-07 | $156.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $39.00K 10-Q · filed 2023-08-14 | $78.00K 10-Q · filed 2023-08-14 | $117.00K derived: sum of 3 quarters · filed 2023-08-14 | $156.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $39.00K 10-Q · filed 2023-05-15 | $78.00K derived: sum of 2 quarters · filed 2023-05-15 | $117.00K derived: sum of 3 quarters · filed 2023-05-15 | $130.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $78.00K derived: sum of 2 quarters · filed 2023-03-07 | $91.00K derived: sum of 3 quarters · filed 2023-03-07 | $91.00K 10-K · filed 2023-03-07 |
| 2021-09-30 | $39.00K 10-Q · filed 2022-11-10 | $52.00K derived: sum of 2 quarters · filed 2022-11-10 | $52.00K 10-Q · filed 2022-11-10 | $65.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $13.00K 10-Q · filed 2022-08-12 | $13.00K 10-Q · filed 2022-08-12 | $26.00K derived: sum of 3 quarters · filed 2022-08-12 | $66.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | $13.00K derived: sum of 2 quarters · filed 2022-05-12 | $53.00K derived: sum of 3 quarters · filed 2022-05-12 | $93.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $53.00K derived: sum of 2 quarters · filed 2022-03-31 | $93.00K derived: sum of 3 quarters · filed 2022-03-31 | $106.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $40.00K 10-Q · filed 2021-11-10 | $80.00K derived: sum of 2 quarters · filed 2021-11-10 | $93.00K 10-Q · filed 2021-11-10 | $102.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $40.00K 10-Q · filed 2021-08-13 | $53.00K 10-Q · filed 2021-08-13 | $62.00K derived: sum of 3 quarters · filed 2021-08-13 | $87.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $13.00K 10-Q · filed 2021-05-14 | $22.00K derived: sum of 2 quarters · filed 2021-05-14 | $47.00K derived: sum of 3 quarters · filed 2021-05-14 | $72.00K derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $34.00K derived: sum of 2 quarters · filed 2021-03-12 | $59.00K derived: sum of 3 quarters · filed 2021-03-12 | $84.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $25.00K 10-Q · filed 2020-10-30 | $50.00K derived: sum of 2 quarters · filed 2020-10-30 | $75.00K 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $25.00K 10-Q · filed 2020-08-12 | $50.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $25.00K 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |